Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Distribution to Unsecured Creditors


RNS Number : 8925O
Redx Pharma plc
24 August 2017
 

24 August 2017

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

REDX PHARMA PLC (in administration)

("Redx" or "the Company")

 

Permission granted for distribution to Unsecured Creditors

 

Redx, the drug discovery and development company, announces that Jason Baker and Miles Needham of FRP Advisory LLP, joint administrators of the Company and of its subsidiary, Redx Oncology Limited ("Oncology") (together, the "Companies") have been granted permission by the High Court to make a distribution to unsecured creditors of the Companies.  The Joint Administrators will shortly be sending unsecured creditors notices of intended dividend, following which claims will be adjudicated and distributions made.  All unsecured creditors will be paid in full (subject to adjudication).  This is a significant step towards the anticipated rescue of the Companies as going concerns and the termination of the Administrations.  A PDF copy of the Order is attached to this notice.

 

Click on, or paste the following link into your web browser, to view the associated PDF document.

 

For further information, please contact:

 

Redx Pharma Plc (in administration)


 

Contact for the Joint Administrators:

Chris French

James Rossiter

 

 

T: + 44 203 005 4000

 

Cantor Fitzgerald Europe (Nomad & Broker)

 

T: +44 20 7894 7000

Phil Davies

 


 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 



About Redx Pharma Plc (in administration)

 

Company website: redxpharma.com

 

Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPIMPTMBJTMPR



Redx Pharma Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use